Chiesi Acquires Amryt Pharma in $1.48B Deal to Broaden Rare Disease Efforts

Chiesi Farmaceutici S.p.A and Amyryr Pharma Plc have announced a new deal wherein the former will acquire the latter in an all-cash transaction topping $1.48 billion. The deal would provide Chiesi access to Amryt’s drug pipeline, with a focus on broadening its efforts in therapeutic development for treatments for rare diseases.

According to Nicole Raleigh, “The transaction also includes Contingent Value Rights (CVRs) of up to an additional $2.50 per ADS, representing an approximate additional $225 million of potential consideration, based on certain milestones being achieved with Amryt’s Filsuvez, that will see the Italian company expand its rare disease medicine portfolio. Filsuvez is used to treat adults and children aged 6 months or older with epidermolysis bullosa (EB), an inherited skin disease that makes the skin very fragile and causes severe blistering and scarring.”

To read more, click here.

(Source: Pharmaphorum, January 9^th, 2022)